Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression
Published version of a preprint
The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
The receptor tyrosine kinase KIT is an established oncogenic driver of tumor growth in certain tumor types, including gastrointestinal stromal tumors, in which constitutively active mutant forms of KIT represent an actionable target for small-molecule tyrosine kinase inhibitors. There is also considerable potential for KIT to influence tumor growth indirectly based on its expression and function in cell types of the innate immune system, most notably mast cells. We have evaluated syngeneic mouse tumor models for antitumor effects of an inhibitory KIT mAb, dosed either alone or in combination with immune checkpoint inhibitors. Anti-KIT mAb treatment enhanced the antitumor activity of anti–CTLA-4 and anti–PD-1 mAbs, and promoted immune responses by selectively reducing the immunosuppressive monocytic myeloid-derived suppressor cell population and by restoring CD8+ and CD4+ T-cell populations to levels observed in naïve mice. These data provide a rationale for clinical investigation of the human KIT-specific mAb KTN0158 in novel immuno-oncology combinations with immune checkpoint inhibitors and other immunotherapeutic agents across a range of tumor types. Mol Cancer Ther; 16(4); 671–80. ©2017 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a mouse colon-26 tumor model, inhibition of receptor tyrosine kinase KIT enhances the anti-tumor activity of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1) by selectively reducing immunosuppressive M-MDSC clusters [54].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [54]
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435 · cited 2×
“001 3 3 1 0 Anti–CTLA-4 þ Anti-KIT (3) 104 <0.”
BackgroundCell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 2×
“KIT (c-KIT, CD117, stem cell factor receptor) is a member of the type III receptor tyrosine kinase family, whose structure comprises five extracellular immunoglobulin (Ig)-like domains, a single transmembrane domain, and intracellular kinase catalytic and regulatory domains (1).”
BackgroundImmune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709 · cited 2×
“These reagents are potent inhibitors of mouse CTLA-4 and PD-1 (43, 44), and as such represent surrogates of the clinically validated immuno-oncology agents against human CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) which have shown remarkable efficacy in multiple clinical indications (21).”
BackgroundKinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 4×
“These reagents are potent inhibitors of mouse CTLA-4 and PD-1 (43, 44), and as such represent surrogates of the clinically validated immuno-oncology agents against human CTLA-4 (ipilimumab) and PD-1 (nivolumab, pembrolizumab) which have shown remarkable efficacy in multiple clinical indications (21).”
BackgroundInfluentialGettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148 · cited 1×
“It is reported that mouse MDSCs do not themselves express detectable KIT protein (53), and we have confirmed by flow cytometry analysis that the M-MDSCs identified during these studies lack detectable KIT expression (data not shown), suggesting that the effect of anti-KIT treatment on M-MDSCs is likely to be indirect…”
BackgroundInflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., & Hanahan, D. (1999) · Genes & Development · doi:10.1101/gad.13.11.1382 · Cited by 946
KIT as a Therapeutic Target in Metastatic Melanoma
Carvajal, R. D. (2011) · JAMA · doi:10.1001/jama.2011.746 · Cited by 888 · cited 2×
“Wild-type KIT expression has also been reported on a range of tumors and hematologicmalignancies, but generally the evidence does not support KIT signaling in these cancers as an oncogenic driver (9, 10).”
Background
Cited by
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
“Further, inhibition of Kit has been demonstrated to enhance the antitumor activity of immune checkpoint inhibitors (anti–CTLA-4 and anti–PD-1) by selectively reducing the immunosuppressive M-MDSCs population in Colon26 mouse tumor model (131).”
BackgroundDevelopment of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 330
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
Wang, Y., Ding, Y., Guo, N., & Wang, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00172 · Cited by 281
Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
Kholodenko, I. V., Kalinovsky, D. V., Doronin, I. I., Deyev, S. M., & Kholodenko, R. V. (2018) · Journal of Immunology Research · doi:10.1155/2018/7394268 · Cited by 185
“The inhibition of c-kit using specific antibodies resulted in a noticeable decrease in the amount of myeloid-derived suppressor cells (MDSC) in the tumor microenvironment and significantly increased the antitumor activity of T cell checkpoint antibody-based inhibitors [102].”
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Metadata
- Authors
- Garton, A. J., Seibel, S., Lopresti-Morrow, L., Crew, L., Janson, N., Mandiyan, S., Trombetta, E. S., Pankratz, S., LaVallee, T. M., & Gedrich, R.
- Affiliations
- Kolltan Pharmaceuticals Inc., New Haven, Connecticut.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2017-04-01
- Volume
- 16
- Issue
- 4
- Pages
- 671-680
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2581440655
- Cited by
- 32
- References
- 58
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 6 · 2018: 2 · 2017: 2
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Keywords
- KIT, immune checkpoint inhibitors, CTLA-4, PD-1, tumor immunosuppression, myeloid-derived suppressor cells, mast cells, CD8+ T cells, CD4+ T cells, combination immunotherapy, gastrointestinal stromal tumor, receptor tyrosine kinase
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Antibodies, Monoclonal, Colonic Neoplasms, Cytotoxicity, Immunologic, Drug Synergism, Humans, Immunosuppression Therapy, Phosphorylation, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins c-kit, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Cell Cycle Checkpoints, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0676
- The paper
- Garton, A. J., Seibel, S., Lopresti-Morrow, L., Crew, L., Janson, N., Mandiyan, S., Trombetta, E. S., Pankratz, S., LaVallee, T. M., & Gedrich, R. (2017). Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0676
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.